Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Average Target Price from Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been given an average rating of “Buy” by the five ratings firms that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have covered the stock in the last year is $36.60.

A number of research firms have recently issued reports on KNSA. JPMorgan Chase & Co. lifted their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Evercore ISI raised their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th.

Insider Activity

In other news, COO Eben Tessari sold 17,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the transaction, the chief operating officer now owns 109,975 shares in the company, valued at $2,955,028.25. This represents a 13.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at $492,449.10. This represents a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,092 shares of company stock valued at $673,039 in the last ninety days. 54.57% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in KNSA. Quarry LP acquired a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $50,000. CWM LLC raised its stake in Kiniksa Pharmaceuticals by 443.0% in the third quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after buying an additional 1,998 shares during the period. nVerses Capital LLC bought a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $80,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $100,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at $189,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

Shares of Kiniksa Pharmaceuticals stock opened at $20.11 on Friday. The company’s fifty day moving average price is $22.26 and its two-hundred day moving average price is $23.11. The firm has a market capitalization of $1.45 billion, a PE ratio of -143.63 and a beta of 0.27. Kiniksa Pharmaceuticals has a 52-week low of $16.56 and a 52-week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The business had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business’s revenue for the quarter was up 67.4% on a year-over-year basis. During the same period last year, the company earned ($0.20) EPS. Analysts predict that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.